Provided by Tiger Trade Technology Pte. Ltd.

ASCLETIS-B

7.545
-0.905-10.71%
Volume:4.17M
Turnover:32.11M
Market Cap:7.94B
PE:-20.39
High:8.455
Open:8.455
Low:7.395
Close:8.450
52wk High:19.860
52wk Low:7.395
Shares:1.05B
HK Float Shares:1.05B
Volume Ratio:2.89
T/O Rate:0.40%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.370
ROE:-28.59%
ROA:-19.64%
PB:2.99
PE(LYR):-20.39
PS:7161.04

Loading ...

ASCLETIS-B (01672) Spends HK$1.76 Million to Buy Back 200,000 Shares on July 29

Stock News
·
Jul 29

Ascletis Pharma - Ind Applications for Asc37 Sq and Oral Formulations to be Submitted in Q3 2026

THOMSON REUTERS
·
Jul 27

Ascletis Announces Once-Monthly Subcutaneously Administered Glp-1R/Gipr/Gcgr Triple Peptide Agonist, Asc37, Demonstrated Superior Weight Loss in a Diet-Induced Obese Mouse Model

THOMSON REUTERS
·
Jul 27

Ascletis Pharma - Announces Asc37 Demonstrates Superior Weight Loss in Obese Mouse Model

THOMSON REUTERS
·
Jul 27

Ascletis’ ASC37 Triple Agonist Delivers 88% Greater Weight Loss Than Tirzepatide; Monthly Injection and Oral BLA Filings Planned for 2026

Bulletin Express
·
Jul 27

Ascletis Says ASC37 Triple Agonist Posts 88% Greater Weight Loss than Tirzepatide in Obese Mice

Reuters
·
Jul 27

Ascletis Pharma Files HKEX Next-day Return Disclosing Share Repurchase for Cancellation

Reuters
·
Jul 27

Ascletis Files HKEX Next-day Disclosure Return Reporting Share Repurchase for Cancellation

Reuters
·
Jul 24

Ascletis Announces Oral Discussion of Asc36_35 Fdc Preclinical Data Demonstrating Superior Weight Loss to Eloralintide/tirzepatide Combination at the 62nd European Association for the Study of Diabetes (easd) Annual Meeting

THOMSON REUTERS
·
Jul 23

Ascletis Pharma Files HKEX Next-day Disclosure Return Reporting Share Repurchase for Cancellation

Reuters
·
Jul 20

ASCLETIS Executes Share Buyback, Spending HK$2.58 Million on July 17

Stock News
·
Jul 17

Ascletis Pharma Files HKEX Next-day Return Disclosing Share Repurchase for Cancellation

Reuters
·
Jul 17

Ascletis Advances First-in-Class Oral GLP-1R/GIPR Combo; IND Filing Planned for Q4 2026

Bulletin Express
·
Jul 15

Ascletis Selects Oral Glp-1/gip Fixed-dose Combo Asc30_48 for Clinical Development in Obesity

Reuters
·
Jul 15

Ascletis Pharma - Ind Submission to FDA for Asc30_48 Fdc Oral Tablets Expected in Q4 2026

THOMSON REUTERS
·
Jul 15

Ascletis Pharma - Asc30_48 Fdc Shows 52% Greater Body Weight Reduction vs Asc30 Monotherapy in Nhp Study

THOMSON REUTERS
·
Jul 15

ASCLETIS-B Chooses Fixed-Dose Combination of Pioneering Oral Small Molecule GIPR Agonist ASC48 and Oral GLP-1R Agonist ASC30 for Clinical Development

Stock News
·
Jul 15

Ascletis Pharma - Selects Fixed-dose Combination of Asc48 and Asc30 for Clinical Development

THOMSON REUTERS
·
Jul 15

Ascletis Accelerates Buyback: Acquires 0.20 Million Shares for HK$2.09 Million, Lifts 2026 Repurchase Total to 0.55 Million

Bulletin Express
·
Jul 14

ASCLETIS-B (01672) Allocates HK$2.09 Million for Share Buyback on July 14

Stock News
·
Jul 14